Nevena Damjanov

Nevena Damjanov

Auto-generated profile, based on publicly available information

Nevena Damjanov

Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2010 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HRHelen J. Ross
Helen J. Ross
GBGeorge R. Blumenschein
George R. Blumenschein
JAJoseph Aisner
Joseph Aisner
NDNevena Damjanov
Nevena Damjanov
ADAfshin Dowlati
Afshin Dowlati
FSFrances A. Shepherd
Frances A. Shepherd
Purpose: This randomized phase II study was initially designed to test the activity of two dose schedules of lapatinib (GW572016H), an oral, reversible, dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human EGFR-2 (HER2/neu; HER2), in chemotherapy-naive patients with non–small cell lung cancer (NSCLC); it was later amended to target patients with bronchioloalveolar carcinoma or no smoking history.

1 March 2018 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
Justin C. BrownJustin C. Brown
Justin C. Brown
ATAndrea B. Troxel
Andrea B. Troxel
BKBonnie Ky
Bonnie Ky
NDNevena Damjanov
Nevena Damjanov
BZBabette S. Zemel
Babette S. Zemel
KSKathryn H. H Schmitz
Kathryn H. H Schmitz

1 August 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
JSJeffrey W. Shevach
Jeffrey W. Shevach
LALisa B. Aiello
Lisa B. Aiello
JLJulie A Lynch
Julie A Lynch
JPJeffrey Petersen
Jeffrey Petersen
LHLori Hoffman-Hogg
Lori Hoffman-Hogg
KMKara N. Maxwell
Kara N. Maxwell
PURPOSE: Telegenetics services can expand access to guideline-recommended cancer genetic testing. However, access is often not distributed equitably to all races and ethnicities. We evaluated the impact of an on-site nurse-led cancer genetics service in a diverse Veterans Affairs Medical Center (VAMC) oncology clinic on likelihood of germline testing (GT) completion. METHODS: We conducted an observational retrospective cohort study of patients who were referred for cancer genetics services at the Philadelphia VAMC between October 1, 2020, and February 28, 2022. We evaluated the association between genetics service (on-site v telegenetics) and likelihood of GT completion in a subcohort of new consults, excluding patients with prior consults and those referred for known history of germline mutations. RESULTS: A total of 238 Veterans, including 108 (45%) seen on site, were identified for cancer genetics services during the study period, with the majority referred for a personal (65%) or family (26%) history of cancer. In the subcohort of new consults, 121 Veterans (54% self-identified race/ethnicity [SIRE]-Black), including 60 (50%) seen on site, were included in the analysis of germline genetic testing completion. In a univariate analysis, patients who were seen by the on-site genetics service had 3.2-fold higher likelihood of completing GT (relative risk, 3.22; 95% CI, 1.89 to 5.48) compared with the telegenetics service. In multivariable regression analysis, the on-site genetics service was associated with higher likelihood of GT completion, but this association was only statistically significant in SIRE-Black compared with SIRE-White Veterans (adjusted RR, 4.78; 95% CI, 1.53 to 14.96; P < .001; P-interaction of race × genetics service = .016). CONCLUSION: An on-site nurse-led cancer genetics service embedded in a VAMC Oncology practice was associated with higher likelihood of germline genetic testing completion than a telegenetics service among self-identified Black Veterans.

1 August 2025 in JCO Precision Oncology
Verified
Journal Article
Open access
STSony Tuteja
Sony Tuteja
MCMari Angelica S. Cayabyab
Mari Angelica S. Cayabyab
GHGlenda Hoffecker
Glenda Hoffecker
LVLisa A. Varughese
Lisa A. Varughese
JNJean de Dieu Ndayishimiye
Jean de Dieu Ndayishimiye
UTUrsina R. Teitelbaum
Ursina R. Teitelbaum
PURPOSE: To determine the feasibility and effectiveness of implementing pretreatment DPYD/UGT1A1 testing in patients with gastrointestinal cancer and its impact compared with a biobank population. MATERIALS AND METHODS: A prospective, nonrandomized implementation trial of pretreatment DPYD/UGT1A1 testing with preemptive dose reduction was conducted in patients initiating treatment with a fluoropyrimidine (FP, [fluorouracil or capecitabine]) or irinotecan. The primary end point was feasibility, defined as proportion of results available prior to cycle 1 of treatment. Secondarily, occurrence of severe treatment-related adverse events (TRAEs), defined as toxicity resulting in hospitalization or emergency department visit, was compared with a biobank population receiving standard dose chemotherapy. RESULTS: Of the 288 patients prospectively tested, 225 (median age 60.7 years, 54% male, 18% Black, 47% colorectal cancer) received a qualifying chemotherapy. Eight of 11 DPYD variant carriers received an FP and eight of 39 UGT1A1 poor metabolizers received irinotecan. The median test turnaround time was 10 days (IQR, 9-13) with 57.4% of results available before cycle 1. Eleven of 16 (69%) participants with a drug-gene interaction (DGI) had results available before chemotherapy initiation and received pharmacogenetic-recommended dose reductions. Compared with the biobank cohort (n = 229), the prospective DGI group experienced fewer severe TRAEs (38% v 65%, P = .123), treatment discontinuations (31% v 47%, P = .356), and treatment modifications (38% v 76%, P = .028). CONCLUSION: Pretreatment DPYD/UGT1A1 testing and dose reduction was feasible, enabling clinicians to make the appropriate chemotherapy dose reductions, reducing occurrence of adverse outcomes. DPYD/UGT1A1 testing is an important precision oncology approach to optimize patient safety.

3 April 2023
Verified
Other
Open access
KRKim Reiss
Kim Reiss
MWMax M. Wattenberg
Max M. Wattenberg
NDNevena Damjanov
Nevena Damjanov
EDElizabeth Prechtel Dunphy
Elizabeth Prechtel Dunphy
MJMona Jacobs-Small
Mona Jacobs-Small
EBEdgar Ben-Josef
Edgar Ben-Josef
Supervised and unsupervised analysis of peripheral blood leukocyte kinetics